Read by QxMD icon Read

Cancer Biomarkers: Section A of Disease Markers

Zhuo Liu, Min Ma, Lei Yan, Shilin Chen, Sha Li, Darong Yang, Xiaohong Wang, Hua Xiao, Hongyu Deng, Haizhen Zhu, Chaohui Zuo, Man Xia
BACKGROUND: Interferon-α (IFN-α) is an adjuvant to chemotherapy and radiotherapy for hepatocellular carcinoma (HCC), but some HCC patients do not respond to treatment with IFN-α. METHODS: We performed loss-of-function and gain-of-function experiments to examine the role of ISG15 in the IFN-α sensitivity of LH86, HLCZ01, SMMC7721, and Huh7 cell lines and tumor samples. RESULTS: The overexpression of ISG15 reduced apoptosis in Huh7 and LH86 cells in the presence of IFN-α, whereas the shRNA-mediated knock down of ISG15 expression increased apoptosis in both Huh7 and LH86 cells...
May 5, 2018: Cancer Biomarkers: Section A of Disease Markers
De-Gang Liu, Lei Xue, Jun Li, Qiang Yang, Jiang-Zhou Peng
BACKGROUND: Circulating tumor cells (CTCs) is a promising biomarker for cancer prognosis and monitoring. Molecular characterizing of CTCs could provide beneficial information on the basis of CTCs counting. OBJECTIVE: To investigate the epithelial-mesenchymal transition (EMT) phenotypes and GALC mRNA expression of CTCs in non-small cell lung cancer (NSCLC) patients. METHODS: We analyzed the baseline number, EMT classification, and GALC expression of CTCs in 47 NSCLC patients using CanPatrol platform and RNA in situ hybridization technique...
May 5, 2018: Cancer Biomarkers: Section A of Disease Markers
Jingjing Zhao, Cong Mai, Desheng Weng, Changlong Chen, Ziqi Zhou, Yuan Liu, Zhiwei Zhou, Peng Wang
BACKGROUND: Rap1GAP, a member of the family of GTPase-activating proteins, is reported to be involved in cancer development and progression. OBJECTIVE: The study aimed to investigate the expression and prognostic value of Rap1GAP in gastric cancer patients. METHODS: Real-time quantitative polymerase chain reaction and western blotting were performed to examine Rap1GAP expression in tumorous and matched adjacent non-tumorous gastric tissues...
May 5, 2018: Cancer Biomarkers: Section A of Disease Markers
Minglei Zhuo, Hanxiao Chen, Tianzhuo Zhang, Xue Yang, Jia Zhong, Yuyan Wang, Tongtong An, Meina Wu, Ziping Wang, Jing Huang, Jun Zhao
BACKGROUND: The PD-L1 antibody atezolizumab has shown promising efficacy in patients with advanced non-small cell lung cancer. But the predictive marker of clinical benefit has not been identified. OBJECTIVE: This study aimed to search for potential predictive factors in circulating blood of patients receiving atezolizumab. METHODS: Ten patients diagnosed with advanced non-small cell lung cancer were enrolled in this open-label observing study...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Wei Ding, Hongbo Tan, Xuemei Li, Yue Zhang, Fang Fang, Yuanyuan Tian, Jin Li, Xinghua Pan
BACKGROUNDS: MicroRNAs (miRNAs) are some RNA molecules that negatively regulate gene expression by binding to the 3'-untranslated region (3'-UTR) of target mRNA molecules. The aim of the study is to investigate the clinical role and functional effects of microRNA-493 (miR-493) in human hepatocellular carcinoma (HCC). METHODS: Expression of miR-493 in 58 cases of HCC tissues and adjacent normal tissues was determined by using quantitative real-time PCR (qRT-PCR) analyses...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Ge Ma, Huaxing Huang, Minghui Li, Li Li, Peng Kong, Yichao Zhu, Tiansong Xia, Shui Wang
Neoadjuvant chemotherapy (NCT) is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) is commonly used as a valid predictor of NCT long-term outcomes. Blood-based tumor biomarkers have the potential to predict response to NCT at early stage non-invasively. We believed plasma CCL5 could be a potential marker to predict NCT of LABC. Its efficiency and possible mechanism was studied in this work. Human Cytokine Antibody Microarray was applied to screen different cytokine concentration in plasma between low histological regression (Low-R) and high histological regression (High-R) patients...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Bing Chen, Ya Li, Yuting He, Chen Xue, Feng Xu
Accumulating evidence suggests that long non-coding RNAs (lncRNAs) have important regulatory functions in gallbladder cancer (GBC) tumorigenesis and can serve as potential novel markers and/or targets for GBC. In this review, we critically discuss the emerging alteration of lncRNAs in GBC, the lncRNAs induced epigenetic regulation, the interaction of lncRNAs with microRNAs and lncRNAs effects on tumor-related signaling pathways. Additionally, contributions of lncRNAs in epithelial-mesenchymal transition process and energy metabolism reprogramming in GBC are also addressed...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Dan Wang, Gui-Min Wen, Wei Hou, Pu Xia
BACKGROUND: This study was carried out to investigate the correlation between CD133 and non-small cell lung cancer (NSCLC) clinicopathological features and its impact on survival of the patients with NSCLC. METHODS: In the first, we detected the level and localization of CD133 protein in NSCLC specimens and confirmed that CD133 expression was closely linked to poor prognosis of NSCLC. Secondly, TCGA genomic data for LUNG (Provisional) was retrieved and analyzed for genetic alterations of CD133 in different lung cancer subtypes...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Lan Hong, Wangsheng Chen, Dongcai Wu, Yifeng Wang
BACKGROUND: Aberrant expression of long non-coding RNAs is involved in the progression of ovarian cancer. However, the clinical significance and biological functions of SNHG3 expression was little known in ovarian cancer (OC). METHODS: The SNHG3 expression in ovarian cancer tissues and paired adjacent normal tissues was detected using quantitative real time polymerase chain reaction (qRT-PCR). Gain-of function and loss-of function assays were performed in ovarian cancer cells to demonstrate the effects of SNHG3 expression on cell proliferation and invasion...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
Nicholas P Hughes, Lingyun Xu, Carsten H Nielsen, Edwin Chang, Sharon S Hori, Arutselvan Natarajan, Samantha Lee, Andreas Kjær, Kian Kani, Shan X Wang, Parag Mallick, Sanjiv Sam Gambhir
BACKGROUND AND OBJECTIVE: To monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents. METHODS: We studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment...
April 13, 2018: Cancer Biomarkers: Section A of Disease Markers
Dora Molina-Ortiz, Carmen Torres-Zárate, Rocío Cárdenas-Cardós, José Martin Palacios-Acosta, Daniel Hernández-Arrazola, Jaime Shalkow-Klincovstein, Erick Díaz-Díaz, Araceli Vences-Mejía
BACKGROUND: Intratumoral up-regulation of genes coding for drug transporters and metabolizing enzymes, such as MDR1 and CYP3A4, after chemotherapy are linked to cancer drug resistance. However their expression in primary soft tissue sarcomas (STS) prior to drug treatment and their role in innate resistance remain unclear. OBJECTIVE: The aim of this study was characterize MDR1 and CYP3A4 expression pattern before to chemotherapy and its clinical implication in pediatric STS...
April 13, 2018: Cancer Biomarkers: Section A of Disease Markers
Anna Babińska, Rafał Pȩksa, Renata Świa Tkowska-Stodulska, Piotr Wiśniewski, Krzysztof Sworczak
BACKGROUND: The role of adopokines in adrenal tumors' hormonal activity remains unclear. Obesity may induce arterial hypertension, disorders of carbohydrate metabolism, and is a risk factor of cardiovascular disease. In patients with subclinical hormone secretion by the adrenal cortex or medulla the risk of metabolic disease is increased. OBJECTIVE: Authors of this retrospective study selected 78 patients with subclinical hormone secretion out of all adrenal incidentaloma patients hospitalized in the Department of Endocrinology and Internal Medicine between 1995 and 2014...
April 10, 2018: Cancer Biomarkers: Section A of Disease Markers
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2018: Cancer Biomarkers: Section A of Disease Markers
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2018: Cancer Biomarkers: Section A of Disease Markers
Chunmei Tian, Lin Zhang, Xiaohua Li, Yanjun Zhang, Jianchang Li, Liang Chen
BACKGROUND: Abnormal expression of miR-192 has been observed in a variety of human cancers, but the expression pattern of miR-192 and its prognostic value in pediatric acute myeloid leukemia (AML) is poorly known. OBJECTIVE: This study was to explore the expression status of miR-192 and its clinical significance in pediatric patients with AML. METHODS: Quantitative RT-PCR was carried out to detect miR-192 expression level in the serum from 97 AML cases and 50 healthy controls...
April 9, 2018: Cancer Biomarkers: Section A of Disease Markers
A Fricke, A F V Cimniak, P V Ullrich, C Becherer, C Bickert, D Pfeifer, J Heinz, G B Stark, H Bannasch, D Braig, S U Eisenhardt
BACKGROUND: Liposarcoma constitute about 13% of all soft tissue sarcoma and are associated with a high risk of metastases. As the preoperative differentiation between benign and malign lipomatous tumors is restricted to magnetic resonance imaging, computed tomography and biopsy, we performed a miRNA array to distinguish dedifferentiated liposarcoma patients from healthy controls and lipoma patients. METHODS: Blood samples of patients with dedifferentiated liposarcoma, healthy controls and lipoma patients were collected...
April 9, 2018: Cancer Biomarkers: Section A of Disease Markers
Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mai Tomiguchi, Aiko Sueta, Hirotaka Iwase
PURPOSE: Plasma and serum cell-free DNA (cfDNA) are useful sources of tumor DNA, but comparative investigations of the tumor mutational status between them are rare. METHODS: we performed droplet digital PCR assay for representative hotspot mutations in metastatic breast cancer (MBC) (ESR1 and PIK3CA) in serum and plasma cfDNA concurrently extracted from the blood of 33 estrogen receptor-positive MBC patients. RESULTS: ESR1 mutations in plasma cfDNA were found in 7 of the 33 patients; ESR1 mutations in serum cfDNA were detected in only one out of 7 patients with ESR1 mutations in plasma cfDNA...
April 7, 2018: Cancer Biomarkers: Section A of Disease Markers
Yu Wang, Xiaorong Jiang, Shasha Wang, Haixia Yu, Tingtin Zhang, Shuan Xu, Wenlong Li, Ellen He, Sven Skog
BACKGROUND: People with biomarkers above cut-off values normally have higher risk to develop pre-malignancies and malignancies. OBJECTIVE: Here we investigate if serological TK1 protein (STK1p), AFP, CEA and PSA below cut-off values predict development of pre-cancer. METHODS: The mean values and the concentration distribution of STK1p, AFP, CEA and PSA were determined in a cohort of 56,178 persons participating a health screening group, consist of people with non-tumor diseases, pre-malignancy and diseases associated with the risk process of malignancy...
April 6, 2018: Cancer Biomarkers: Section A of Disease Markers
Giuseppe Latini, Claudio De Felice, Alessandro Barducci, Lucia Dipaola, Mattia Gentile, Maria Grazia Andreassi, Mario Correale, Giorgio Bianciardi
Cancer is the most important cause of death worldwide, and early cancer detection is the most fundamental factor for efficacy of treatment, prognosis, and increasing survival rate. Over the years great effort has been devoted to discovering and testing new biomarkers that can improve its diagnosis, especially at an early stage. Here we report the potential usefulness of new, easily applicable, non-invasive and relatively low-cost clinical biomarkers, based on abnormalities of oral mucosa spectral reflectance and fractal geometry of the vascular networks in several different tissues, for identification of hereditary non-polyposis colorectal cancer carriers as well for detection of other tumors, even at an early stage...
April 6, 2018: Cancer Biomarkers: Section A of Disease Markers
Daniela Liberati, Ilaria Marzinotto, Cristina Brigatti, Erica Dugnani, Valentina Pasquale, Michele Reni, Gianpaolo Balzano, Massimo Falconi, Lorenzo Piemonti, Vito Lampasona
BACKGROUND: Sensitive and specific biomarkers of Pancreatic Ductal Adenocarcinoma (PDAC) are desperately needed to allow early diagnosis and improve patient's survival. Ezrin autoantibodies were recently described as present in 93% of PDAC patients and 40% of healthy subjects who later developed PDAC. However, another prospective study failed to replicate these findings. Both studies were based on the use of a solid phase ELISA immunoassay. OBJECTIVE: We aimed at re-evaluating the usefulness of Ezrin autoantibodies as PDAC biomarkers using the Luciferase Immuno Precipitation System (LIPS), an alternative immunoassay format that found successful application for the measurement of autoantibodies against pancreatic autoantigens...
April 3, 2018: Cancer Biomarkers: Section A of Disease Markers
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"